Navigation Links
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
Date:5/26/2009

oom or hospital setting. These formulations are bioequivalent, meaning doses do not need to be adjusted when converting from IV to oral. The IV formulation of Vimpat(R) does not require dilution prior to administration.

Vimpat(R) was approved by the U.S. Food and Drug Administration in October 2008 for the adjunctive treatment of partial onset seizures in patients with epilepsy age 17 and over. Vimpat(R) has been designated as a Schedule V controlled substance by U.S. regulators.

In August 2008, the European Commission approved Vimpat(R) for the adjunctive treatment of partial onset seizures with or without secondary generalization in patients with epilepsy age 16 and over. Vimpat(R) is available in Germany, the U.K., Greece, Austria, Denmark, Sweden, and Netherlands, with other European countries to follow.

Vimpat(R) offers new way of targeting pathways involved in seizure onset

Preclinical studies indicate that Vimpat(R) has a novel mechanism of action, although the precise mechanism by which Vimpat(R) exerts its antiepileptic effect in humans is not yet clear.

In preclinical studies, the mechanism of action for Vimpat(R) has been shown to involve the modulation of sodium channel activity in the nervous system. Sodium channels play a crucial role in regulating the activity of the nervous system to help nerve cells communicate. Sometimes sodium channels are abnormally overactive and nerve cells become too excited, which may produce a seizure. The mechanism of action for Vimpat(R) is thought to reduce this sodium channel over-activity by enhancing the longer lasting inactive state of the channel, a different action compared with current sodium channel blocking drugs. This action then regulates the activity of over-excited nerve cells, which may contribute to the control of seizures.

Preclinical studies also suggest that Vimpat(R) binds to the collapsin response mediat
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... ., Aug. 22, 2014  Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats three types ... of all cervical cancer. When tested in several ... HPV-18 and HPV-11 cells, according to Louise T. Chow ... the findings at the Seattle conference. ...
(Date:8/22/2014)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... technologies and products for advanced microarray diagnostics, today ... Service Agreement to contract with a UK-based company ... the initial phase of this agreement, SQI will ... of one of the customer,s assays, operational on ...
(Date:8/21/2014)... Ill. , Aug. 21, 2014 ... Baxter International Inc. today announced positive results from ... 855, an investigational, extended half-life recombinant factor VIII ... [Antihemophilic Factor (Recombinant)], which met its primary endpoint ... prophylaxis arm compared to the on-demand arm. ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... in combination with the most commonly used doses of ... patients with mixed dyslipidemiaORLANDO, Fla., March 29 Data ... TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with rosuvastatin ... TRILIPIX 135 mg in combination with rosuvastatin calcium 5 ...
... March 29 A new analysis from the,JUPITER ... the risk of venous thromboembolism (VTE) by 43% ... with low to normal cholesterol levels and elevated,high-sensitivity ... the 58th Annual American College of Cardiology Scientific ...
Cached Medicine Technology:New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5CRESTOR(R) Reduced Risk of Blood Clots in the Veins 2CRESTOR(R) Reduced Risk of Blood Clots in the Veins 3CRESTOR(R) Reduced Risk of Blood Clots in the Veins 4
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Mi40x ... uses university-proven research to show people how they can use ... muscle in only a matter of weeks has caught the ... “Ben Pakulski is one of the most well-known bodybuilders in ... the body he has today, that in itself is a ...
(Date:8/22/2014)... Paying tuition and other related educational ... year for four nurse educators pursuing advanced degrees, thanks ... Nursing Foundation for Nursing Education . This year’s recipients ... more than in 2013, thanks to these named NLN ... Isaac Marcil Endowment Funds, both donated by Kathy Mershon; ...
(Date:8/22/2014)... Wisconsin (PRWEB) August 22, 2014 Mueller ... for Plantar Fasciitis, an exciting new product that provides ... you to stay active while you heal. The package ... is truly a new technology – it is not ... , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
(Date:8/22/2014)... A new study of self-awareness by Kessler Foundation ... may be able to improve their self-awareness through ... of print on July 2 in NeuroRehabilitation ... D. Chiaravalloti & John DeLuca: Metacognitive knowledge and ... 10.3233/NRE-141113). Self-awareness is one,s ability to recognize cognitive ...
(Date:8/22/2014)... 2014 Menstrual leaks risk stains and ... Fla., decided that there needed to be a better ... and producible in design variations, the Safety Net optimizes ... which avoids embarrassment and promotes peace of mind. The ... , The original design was submitted to the Fort ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... gene (MTDH) plays a role in both cancer metastasis ... Press in the January 6th issue of the journal ... therapeutic target for high risk breast cancers. , "Most ... succumb to recurrent tumors that spread to distant vital ...
... , The Fifth International Conference on Cell Therapy ... on stem cells for non-cardiac organ injury. The session ... disease and diabetes, bone marrow cells for stroke patients, ... , Highlights from other sessions include the first human ...
... in the U.S. each year have been exposed to alcohol or ... by the National Center on Substance Abuse and Child Welfare. If ... remain in foster care longer, and chances are very low that ... study led by Joseph P. Ryan, a faculty member in the ...
... PR Newswire Staff Volunteer Time As Part ... InitiativeCLEVELAND, Jan. 5 Ronald McDonald House of ... two non-profit organizations serving the Cleveland community, were ... hours from PR Newswire,s Cleveland staff in 2008, ...
... cost Medicaid hundreds of millions of dollars annually in ... could not only improve outcomes but also save substantial ... examined records of nearly 150,000 people in six states. ... more than they think," said Robin E. Clark, PhD, ...
... OF PLASTIC SURGEONSARLINGTON HEIGHTS, Ill., Jan. 5 The ... Plastic Surgeons:Can The US Really Cut Health Care Spending? ... is one of the strongest sectors of the ailing ... health care spending is not probable. The author, who ...
Cached Medicine News:Health News:Gene plays dual role in breast cancers with poor prognosis 2Health News:Conference on cell therapy includes new session on stem cells for non-cardiac organ injury 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 2Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 4Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 5Health News:Substance abuse adds millions to Medicaid's total health care costs 2Health News:Substance abuse adds millions to Medicaid's total health care costs 3Health News:Plastic and Reconstructive Surgery...In Brief 2Health News:Plastic and Reconstructive Surgery...In Brief 3
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: